Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD?

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Current Drug Targets

• Publication date

  2010-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/138945010790309867PMID 20210767
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Crohn's disease, hepatosplenic T-cell lymphoma and no biological therapy: are we barking up the wrong tree?

  2009cited by this paper
• Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study.

  2009cited by this paper
• Adalimumab safety in global clinical trials of patients with Crohn's disease

  2009cited by this paper
• Lack of association between cervical dysplasia and IBD: A large case–control study

  2009cited by this paper
• Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

  2009cited by this paper
• S1133 Hepatosplenic T-Cell Lymphoma (HSTCL) and Inflammatory Bowel Disease (IBD): A Rare Complication After Long-Term Thiopurine Exposure: Case Report and Systematic Review of the Literature

  2009cited by this paper
• Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease.

  2009cited by this paper
• Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis.

  2009cited by this paper
• Prevalence of infectious pathogens in Crohn's disease.

  2009cited by this paper
• Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis.

  2008cited by this paper
• Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

  2008cited by this paper
• Screening differences and risk of cervical cancer in inflammatory bowel disease

  2008cited by this paper
• Hepatosplenic T cell lymphoma in inflammatory bowel disease

  2008cited by this paper
• Higher Incidence of Abnormal Pap Smears in Women With Inflammatory Bowel Disease

  2008cited by this paper
• Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.

  2008cited by this paper
• Risk factors for opportunistic infections in patients with inflammatory bowel disease.

  2008cited by this paper
• 818 Excess Risk of Lymphoproliferative Disorders (LPD) in Inflammatory Bowel Diseases (IBD): Interim Results of the Cesame Cohort

  2008cited by this paper
• Colorectal cancer in Crohn's disease--review of a 56-year experience in Karolinska Institute University Hospital.

  2008cited by this paper
• Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

  2007cited by this paper
• Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial

  2007cited by this paper
• Hepatosplenic T‐cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale?

  2007cited by this paper
• Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

  2007cited by this paper
• Certolizumab pegol for the treatment of Crohn's disease.

  2007cited by this paper
• The non‐Hodgkin lymphomas: A review of the epidemiologic literature

  2007cited by this paper
• Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy

  2007cited by this paper
• Maintenance therapy with certolizumab pegol for Crohn's disease.

  2007cited by this paper
• Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take "toll" ?

  2006cited by this paper
• Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

  2006cited by this paper
• Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

  2006cited by this paper
• Risk factors for ulcerative colitis‐associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: Results of a population‐based study

  2006cited by this paper
• Recent trends in the epidemiology of inflammatory bowel diseases: up or down?

  2006cited by this paper
• Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

  2006cited by this paper
• Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

  2006cited by this paper
• Infliximab for induction and maintenance therapy for ulcerative colitis.

  2005cited by this paper
• Infliximab and newly diagnosed neoplasia in Crohn’s disease: a multicentre matched pair study

  2005cited by this paper
• Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

  2005cited by this paper
• Risk of haematopoietic cancer in patients with inflammatory bowel disease

  2005cited by this paper
• Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

  2005cited by this paper
• Do steroids increase lymphoma risk? A case–control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis

  2005cited by this paper
• A Prospective Randomized Observer-Blind 2-Year Trial of Azathioprine Monotherapy versus Azathioprine and Olsalazine for the Maintenance of Remission of Steroid-Dependent Ulcerative Colitis

  2004cited by this paper
• The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.

  2004cited by this paper
• The epidemiology of non-Hodgkin's lymphoma

  2004cited by this paper
• Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County

  2004cited by this paper
• Infliximab maintenance therapy for fistulizing Crohn's disease.

  2004cited by this paper
• Epstein-Barr Virus Viral Load in Crohn’s Disease: Effect of Immunosuppressive Therapy

  2004cited by this paper
• Safety Aspects of Infliximab in Inflammatory Bowel Disease Patients

  2004cited by this paper
• Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes.

  2003cited by this paper
• Immunomodulators and “On Demand” Therapy with Infliximab in Crohn's Disease: Clinical Experience with 400 Infusions

  2003cited by this paper
• Epstein–Barr virus infection in colorectal neoplasms associated with inflammatory bowel disease: detection of the virus in lymphomas but not in adenocarcinomas

  2003cited by this paper
• TNF Regulates Chemokine Induction Essential for Cell Recruitment, Granuloma Formation, and Clearance of Mycobacterial Infection1

  2002cited by this paper
• Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.

  2002cited by this paper
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

  2002cited by this paper
• The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.

  2001cited by this paper
• Inflammatory bowel disease is not associated with an increased risk of lymphoma.

  2001cited by this paper
• Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.

  2001cited by this paper
• Cancer risk in patients with inflammatory bowel disease

  2001cited by this paper
• Risk of malignancy among patients with rheumatic conditions

  2000cited by this paper
• Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low

  2000cited by this paper
• Risk of lymphoma in inflammatory bowel disease

  2000cited by this paper
• Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

  1999cited by this paper
• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  1998cited by this paper
• Epstein‐Barr virus in B‐cell lymphomas associated with chronic suppurative inflamation

  1997cited by this paper
• Rheumatoid arthritis and cancer risk.

  1996cited by this paper
• Cancer in Crohn's disease: dispelling the myths.

  1994cited by this paper
• Crohn's disease and cancer: a population-based cohort study.

  1994cited by this paper
• Extracolonic malignancies in inflammatory bowel disease

  1991cited by this paper
• INCREASED FREQUENCY OF POSTTRANSPLANT LYMPHOMAS IN PATIENTS TREATED WITH CYCLOSPORINE, AZATHIOPRINE, AND PREDNISONE

  1989cited by this paper
• Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study.

  1988cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• The causal effect of inflammatory bowel disease on diffuse large B-cell lymphoma: two-sample Mendelian randomization study

  2023cites this paper
• Discovery of a Non-competitive TNFR1 Antagonist Affibody with Picomolar Monovalent Potency That Does Not Affect TNFR2 Function.

  2023cites this paper
• Primary Cutaneous B-cell Lymphoma Leg-type Related to a Tumour Necrosis Factor Alpha Inhibitor

  2022cites this paper
• Polyphenols in the Prevention of Ulcerative Colitis

  2019cites this paper
• 2019 Expert opinion on biological treatment use in inflammatory bowel disease management.

  2019cites this paper
• Safe use of infliximab for the treatment of severe perianal Crohn’s disease after diagnosis and treatment of lymphoma

  2018cites this paper
• Overview of lymphoma

  2017cites this paper
• Pathogenic Role of Cytokines and Effect of Their Inhibition in Psoriasis

  2017cites this paper
• Next generation antibody drugs: pursuit of the 'high-hanging fruit'

  2017cites this paper
• Evaluation of egg white ovomucin-based porous scaffold as an implantable biomaterial for tissue engineering.

  2017cites this paper
• Exploring the potential of glycogen synthase kinase-3 (GSK3) mediated therapy in castrate-resistant prostate cancer

  2016cites this paper
• Oral delivery of macromolecular drugs: Where we are after almost 100years of attempts.

  2016cites this paper
• Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience

  2016cites this paper
• Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease.

  2016cites this paper
• Safety profile of anti‑tumor necrosis factor therapy in inflammatory bowel disease – a single center experience

  2016cites this paper
• Amphiphilic nucleic acid conjugates for transfection of differentiated intestinal cells

  2016cites this paper
• Patient considerations in the management of ulcerative colitis – role of vedolizumab

  2015cites this paper
• Update on psoriasis immunopathogenesis and targeted immunotherapy

  2015cites this paper
• Risk and Clinical Characteristics of Lymphoma in Korean Patients With Inflammatory Bowel Diseases: A Multicenter Study

  2015cites this paper
• Curcumin and Inflammatory Bowel Disease: Potential and Limits of Innovative Treatments

  2014cites this paper
• Have Biologics Changed the Natural History of Crohn's Disease?

  2014cites this paper
• Polyphenols in the Prevention of Ulcerative Colitis: Past, Present and Future

  2014cites this paper
• Pre-clinical evaluation of soybean-based wound dressings and dermal substitute formulations in pig healing and non-healing in vivo models

  2014cites this paper
• Medicinal Efficacy of Indian Herbal Remedies for the Treatment of Arthritis

  2013cites this paper
• Indian Medicinal Plants and Spices in the Prevention and Treatment of Ulcerative Colitis

  2013cites this paper
• Efficacy of anti-TNF-alpha monoclonal antibodies in inflammatory bowel disease treatment

  2013influential citation
• Meta-analysis: serious adverse events in Crohn's disease patients treated with TNF-alpha inhibitors.

  2013cites this paper
• Methotrexate: should we start using it in clinical practice?

  2013cites this paper
• Characterization of inhibitory T cells induced by an analog of type II collagen in an HLA-DR1 humanized mouse model of autoimmune arthritis

  2012cites this paper
• Crohn’s Disease: A Brief and Elementary Overview

  2012cites this paper
• Synthesis and Characterization of Soybean-Based Hydrogels with an Intrinsic Activity on Cell Differentiation

  2012cites this paper
• Putting together the psoriasis puzzle: an update on developing targeted therapies

  2012cites this paper
• Signaling and Regulation Cytokine Induction of Tumor Necrosis Factor Receptor 2 Is Mediated by STAT 3 in Colon Cancer Cells

  2011cites this paper
• Inflammatory bowel disease.

  2011cites this paper
• Bronchiectasis and autoimmune disease

  2011cites this paper
• Cytokine Induction of Tumor Necrosis Factor Receptor 2 Is Mediated by STAT3 in Colon Cancer Cells

  2011cites this paper
• Cytokine blockade in inflammatory bowel diseases.

  2011cites this paper
• Immunosuppressive and Cytotoxic Therapy: Pharmacology, Toxicities, and Monitoring

  2011cites this paper
• Modulation of collagen-induced arthritis by adenovirus-mediated intra-articular expression of modified collagen type II

  2010cites this paper
• Epstein-Barr Virus, Lymphoma Risk and the Potential Role of HIV Infection in IBD Patients Undergoing Immunosuppression

  2010cites this paper
• Journal of Traditional and Complementary Medicine

  year unknowncites this paper